Shinhan Securities is hosting an event inviting institutional investors to its biotech forum in Daejeon. During this event, Orum Therapeutics will hold a CEO investor round-table with institutional investors at the Hotel Interciti on July 9th from 4:10 PM to 5:00 PM KST and introduce the company's proprietary degrader-antibody conjugate (DAC) platform and strategic business initiatives.
Orum to participate in Shinhan Bio Forum in Daejeon
Previous
Previous
Advancing ORM-1153 into the Clinic: Conference Call on IND Clearance & Clinical Study Overview
Next
Next

